[Differences between oral antidiabetics].
Bleskestad
Inger Hjørdis
IH
Endokrinologisk seksjon Medisinsk avdeling Sentralsjukehuset i Rogaland.
Birkeland
Kåre Inge
KI
D000284:Administration, Oral; D002219:Carbamates / Q000493:pharmacokinetics; D003510:Cyclohexanes / Q000493:pharmacokinetics; D003920:Diabetes Mellitus / Q000188:drug therapy*; D005913:Glipizide / Q000008:administration & dosage / Q000493:pharmacokinetics; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D000077715:Nateglinide; D010649:Phenylalanine / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D010880:Piperidines / Q000493:pharmacokinetics; D013453:Sulfonylurea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics
D002219:Carbamates; D003510:Cyclohexanes; D007004:Hypoglycemic Agents; D007328:Insulin; D010880:Piperidines; D013453:Sulfonylurea Compounds; D000077715:Nateglinide; D010649:Phenylalanine; C072379:repaglinide; C057619:glimepiride; D005913:Glipizide
Forskjeller mellom perorale antidiabetika.